Affy Leverages Hyseq Settlement into Joint Array Venture, N-Mer | GenomeWeb

For cash-strapped Hyseq, a cash settlement with Affymetrix in its four-year patent battle would have been a nice shot in the arm.

The company only has $16.5 million in cash and $39 million in total assets (as of Sept. 30), and that’s with generous $20 million infusions from guardian angel-chairman George Rathman.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.